Quest Diagnostics (NYSE:DGX) (NYSE: DGX) is a leading provider of diagnostic information services, offering routine and specialized laboratory testing and related healthcare services. Serving patients through a national network of laboratories and patient service centers, the company collaborates with physicians, hospitals, health systems, employers and insurers to deliver insights that support the prevention, detection and monitoring of disease.
The company’s portfolio spans a broad range of testing services, including routine blood chemistry, anatomic pathology, molecular and genomic diagnostics, and drug and toxicology screening. Quest Diagnostics also offers informatics solutions, data analytics tools and digital health technologies designed to streamline clinical decision-making and improve patient outcomes. Its capabilities include advanced genetic testing for hereditary conditions, oncology panels, women’s health assays and occupational health screenings.
Quest Diagnostics traces its origins to 1967, when Corning Glass Works established a medical laboratory division. After several acquisitions and expansions, the laboratory business was spun off as a public company in 1996. Over the following decades, Quest Diagnostics grew through strategic acquisitions of regional lab networks and investments in technology, establishing itself as a cornerstone of the U.S. clinical diagnostics industry. The company is headquartered in Secaucus, New Jersey.
Today, Quest Diagnostics maintains operations in all 50 U.S. states, Puerto Rico and select international markets, ensuring broad access to testing and information services. Under the leadership of President and Chief Executive Officer Jim Davis, the company continues to pursue innovation in diagnostics and healthcare informatics, with a focus on expanding its service offerings and enhancing the patient experience.
